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An association between chronical obstructive
pulmonary disease (COPD) and abdominal aortic
aneurysm (AAA) has been reported. The preva-
lence of AAA among patients with COPD has been
found to be 7% to 11%,1,2 and most population-
based screening programs report prevalences of 4%
to 6%.3-12 The association has been explained in
part as common degradation of elastic tissue.
Increased elastolytic activity has been described in
serum and lungs of patients with COPD13-17 and
in serum and aortas of patients with AAA.18-22
However, if only part of the pathogenesis of AAA
and COPD is common, then AAA may behave dif-
ferently among patients with COPD than among
patients without COPD. Thus strategy in the man-
agement of COPD and of small AAAs may have to
be revised. To investigate the natural history of
AAA among patients with coexisting COPD, epi-
demiologic, clinical, and serologic data were stud-
ied in a population-based mass screening trial of
therapy for AAA. 
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Purpose: To study the relation between abdominal aortic aneurysms and chronical
obstructive pulmonary disease (COPD), in particular the suggested common elastin
degradation caused by elastase and smoking.
Methods: A cross-sectional population study and a prospective cohort study of small abdom-
inal aortic aneurysms was performed in a community setting. All previous diagnoses record-
ed in a hospital computer database were received for 4404 men 65 to 73 years of age who
had been invited to a population screening for abdominal aortic aneurysm. One hundred
forty-one men had AAA (4.2%). They were asked to participate in an interview, a clinical
examination, and collection of blood sample. Men with an abdominal aortic aneurysm 3 to
5 cm in diameter were offered annual ultrasound scans to check for expansion. 
Results: Among patients with COPD 7.7% had abdominal aortic aneurysms (crude odds
ratio = 2.05). The adjusted odds ratio, however, was only 1.59 after adjustment for
coexisting diseases associated with abdominal aortic aneurysm (P = .13). The mean
annual expansion was 2.74 mm per year among patients with COPD, 2.72 among
patients without COPD, and 4.7 mm among patients who used oral steroids compared
with 2.6 among patients who did not use steroids (P < .05). Concentration of serum
elastin peptide and plasma elastase–a 1-antitrypsin complexes correlated negatively with
forced expiratory volume in the first second (FEV1) among patients with COPD.
However, multivariate regression analysis showed that concentration of serum elastin
peptide, therapy with b -agonists, and FEV1 correlated positively with degree of expan-
sion but that concentration of plasma elastase–a 1-antitrypsin complexes and serum a 1-
antitrypsin did not influence expansion, suggesting that elastase plays an important role
in the pathogenesis of COPD but not of abdominal aortic aneurysm. 
Conclusion: The high prevalence of abdominal aortic aneurysm among patients with
COPD is more likely to be caused by medication and coexisting diseases rather than a
common pathway of pathogenesis. (J Vasc Surg 1998;28:226-33.)
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METHODS
Cross-sectional population study. Personal
identification numbers, names, and addresses of all
men in Viborg county 65 to 73 years of age were
loaded into a computer.7 After randomization, half
the men (4404) were invited to undergo an abdom-
inal ultrasonographic scan at their regional hospital.
At the same time, all their previous diagnoses
recorded in hospital computer databases and coded
according to World Health Organization classifica-
tion were received from a different registry. The
codes were transformed into COPD, hypertension,
previous myocardial infarction, angina pectoris,
stroke, arrhythmia, and lower limb arteriosclerosis
according to the classification shown in Table I and
inserted manually into the database. No attempt was
made to confirm or supply the recorded diagnoses at
the screening sessions. AAA was defined as having an
anteroposterior infrarenal aortic diameter of 30 mm
or more. Patients with an AAA 3 to 5 cm in diame-
ter were offered annual follow-up examinations to
check for expansion. Patients with an AAA 5 cm or
more in diameter were referred for vascular surgical
intervention.
Prospective study of diagnosed small abdom-
inal aortic aneurysms. Patients with an AAA were
invited to consult the physician (JSL) conducting
the trial for information, examination, and a second
scan so that the same observer and scanner would be
used for follow-up scans. Present use of medication
and smoking habits were recorded. Height and
weight were measured, and body mass index was cal-
culated. Blood pressure was measured on each arm,
and the higher pressure was recorded. Systolic ankle
blood pressure was measured bilaterally, and the
lower pressure was recorded. Functional vital capac-
ity and forced expiratory volume in the first second
(FEV1) were measured three times at the initial con-
sultation with an electronic spirometer (Vitalograph
Escort spirometer; Spiropharma) reported to corre-
late extremely well with a model S wedge bellows
spirometer in regard to functional vital capacity and
FEV1.23 The highest volumes were recorded.
Calibration was performed for each patient. 
One to four days after the initial examination,
subjects who lived less than 30 km from the hospital
were asked for a blood sample. The serum samples
were left for coagulation for 45 minutes. Serum and
plasma samples were then obtained and frozen at
–21° C. After a countywide screening for AAA, all
samples were thawed, and concentrations of serum
elastin peptide,18 serum procollagen III-N-terminal
propeptide,24,25 serum a 1-antitrypsin, and serum
and plasma elastase– a 1-antitrypsin complexes were
determined. 
At the annual follow-up scans, the same observ-
er and the same scanner were used as at the primary
consultation. The mean annual expansion was calcu-
lated as follows: [(Current anteroposterior diameter
– Initial anteroposterior diameter) ÷ Days of obser-
vation] · 364.25 days. The observer was blinded to
the results of the analysis of blood samples.
Noncommercial enzyme-linked immunosorbent
assays were set up for measurement of serum elastin
peptides and serum and plasma elastase– a 1-anti-
trypsin complexes. The methods were reported ear-
lier.18,26 The trial was approved by the local scientif-
ic ethics committee and reported to the Central
Control of Registers. Chi-square tests, Mantel-
Haenzsel stratified analysis, Mann-Whitney tests,
bivariate linear regression analyses, and multiple lin-
ear regression analyses were performed.
RESULTS
Overall, 3344 of 4404 men invited (76%) attend-
ed the screening, and 141 had AAA (4.2%). A diag-
nosis of COPD was recorded for 280 (6.4%) of the
men invited. Of these, 208 (74.2%) attended the
screening, and 16 (7.7%) had AAA. Thus the crude
odds ratio for having AAA among patients with
COPD compared with patients without COPD was
2.05 (95% confidence interval [CI], 1.14 to 3.62; P
= .01). 
Table II shows the frequencies of coexisting dis-
Table I. Definitions of diseases associated with abdominal aortic aneurysm
Disease WHO classification code
Arterial hypertension 40000-40499, 41009, 41109, 41209, 41309, 43100 + 09, 43309, 43409, 43509, 43-700-99
Acute myocardial infarction 41009 + 41099
Chronic obstructive pulmonary disease 41109-41199, 41309-41399
Angina pectoris 49100-49309, 51700-51709
Lower limb atherosclerosis 44009 + 20 + 30 + 39 + 99, 44300-44599
Stroke or transient cerebral ischemia 43100-43299, 43309 + 99, 43409 + 99, 43509 + 99, 43601 + 90 + 99
WHO, World Health Organization.
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eases associated with AAA1,7,27-41 among patients
with COPD and patients without COPD. An
increased prevalence of coexisting AAA-associated
disease was found among patients with COPD.
Stratified Mantel-Haenzsel analysis adjusted for
coexisting AAA-associated diseases bisected
increased risk for AAA in patients with COPD to
1.59 (Mantel-Haenszel weighted odds ratio, 1.59;
95% CI, 0.92 to 2.77; P = .13). Mean anteroposte-
rior diameter of the aneurysm was 19.5 mm among
patients with COPD and 18.7 mm among patients
without COPD (P = .23 adjusted for age). Mean
AAA diameter among patients with COPD was 37.1
mm and among patients without COPD was 37.9
mm (P = .56 adjusted for age).
Table III compares the mean values of the results
of the blood analysis for patients with COPD and
AAA and patients without COPD but with AAA.
Quantities of serum elastin peptides and plasma elas-
tase– a 1-antitrypsin complexes were significantly
higher among patients with COPD. Furthermore,
bivariate regression analysis with FEV1 as the depen-
Table II. Frequency of diseases associated with abdominal aortic aneurysm among men with and men
without chronic obstructive pulmonary disease (COPD)
Patients with COPD Patients without COPD
AAA* Population† AAA* Population†
Disease (n = 16) (n = 280) (n = 123) (n = 4124)
Hypertension 5 (31.3) 26 (9.3)‡ 33 (26.8) 233 (5.6)
Previous acute myocardial infarction 3 (18.8) 29 (10.4)‡ 20 (16.3) 271 (6.6)
Arrhythmia§ 3 (18.8) 23 (8.2)‡ 6 (4.9) 143 (3.5)
Angina pectoris 1 (6.3) 24 (8.6)‡ 13 (10.6) 198 (4.8)
Previous lower limb atherosclerosis 1 (6.3) 11 (3.9) 5 (4.1) 111 (2.7)
Previous cardiac insufficiency, compensated or uncompensated 3 (18.8) 48 (17.1)‡ 11 (8.9) 178 (4.3)
Previous stroke or transient cerebral ischemia 1 (6.3) 6 (2.1) 5 (4.1) 122 (3.0)
Previous presence of one or more of the diseases 10 (62.5)‡ 104 (37.1)‡ 59 (48.0) 743 (18.2)
Values in parentheses are percentages. 
Mantel-Haenszel stratified analysis with or without AAA and with or without COPD controlling for presence or absence of one or more
of the AAA-associated diseases. Odds ratio, 1.59 (95% CI, 1.02 to 2.77).
AAA, Abdominal aortic aneurysm. 
*Frequency of AAA-associated disease among men with COPD and AAA tested against the frequency among men without COPD who
had AAA. 
†Frequency of AAA-associated disease in the population with COPD tested against the frequency in the population without COPD.
Chi-square test P < .05. 
§Previous cardiac arrhythmia, atrial fibrillation, tachycardia, or similar disorder.
Table III. Serologic markers of the metabolism of the matrix proteins among patients with abdominal
aortic aneurysm with and without chronic obstructive pulmonary disease (COPD)
Patients with COPD Patients without COPD
(n = 15) (n = 68)
Serologic test Mean value* RFEV1 Mean value* RFEV1 RFEV1, ALL
Serum elastin peptide (mg/L) 39.5 (13.8)‡ –0.37 32.7 (9.7) –0.14 –0.22 
(–0.78 to 0.16) (–0.65 to 0.09) (–0.41 to –0.02)§
Serum elastase–a 1-antitrypsin complexes (mg/L) 310 (279) –.26 181 (123) –0.31 –0.35 
(–0.69 to 0.31) (–0.48 to –0.12)§ (–0.50 to –0.17)§
Plasma elastase–a 1-antitrypsin complexes (mg/L) 88.5 (44)‡ –0.69 67.2 (45) –0.13 –0.23
(–0.89 to –0.25)§ (–0.33 to 0.07) (–0.41 to –0.05)§
a 1-Antitrypsin (g/L) 1.57 (0.37) –0.35 1.47 (1.07) 0.08 0.05
(–0.74 to 0.12) (–0.12 to 0.28) (–0.14 to 0.23)
Procollagen (mg/L) 36.9 (23.4) 0.20 35.5 (12.5) 0.10 0.12
(–0.42 to 0.70) (–0.12 to 0.32) (–0.09 to 0.32)
*Value in parentheses is standard deviation.
Values in parentheses are 95% confidence limits.
Mann-Whitney rank sum test P < .05.
§Spearman squared correlation coefficient > 0.
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dent variable was performed for in each group.
Quantities of plasma elastase– a 1-antitrypsin com-
plexes correlated negatively with FEV1 among
patients with COPD but not among patients with-
out COPD.
Nineteen AAA were more than 5 cm in diameter,
and the patients were referred for vascular surgical
intervention. The other 122 patients were consid-
ered to have small AAAs and were offered annual
follow-up examinations. Of these, 110 men with a
small AAA underwent examinations the following
year. Among the men with a small AAA, 99 had
been previously asked for a blood sample, 83 under-
went blood sampling, and 79 underwent follow-up
blood sampling. Table IV compares expansion rates
for dichotomous variables. Patients given oral thera-
py with steroids and those who smoked had signifi-
cantly more expansion. Men taking b -blockers had
insignificantly less expansion, and those who used b -
agonists had insignificantly more expansion.
Bivariate regression analysis showed that initial size
of an AAA and quantities of serum elastin peptide
correlated positively with expansion, whereas con-
centration of plasma and serum elastase– a 1-anti-
trypsin complexes and a 1-antitrypsin, ankle and
brachial blood pressure, body mass index, FEV1,
functional vital capacity, and age did not seem to
influence expansion. 
Table V shows the results of a multiple regres-
sion analysis involving some of the aforementioned
variables. Initial size of the AAA, concentration of
serum elastin peptides, b -agonist treatment, and
FEV1 were independent positively correlated predic-
tors of expansion, whereas concentration of plasma
elastase–a 1-antitrypsin complexes, concentration of
a 1-antitrypsin, diastolic blood pressure, smoking,
and steroid treatment did not influence expansion. 
Table VI shows the mean concentration of serum
elastin peptides, plasma and serum elastase–a 1-anti-
trypsin complexes, and a 1-antitrypsin in relation to
Table IV. Mean annual expansion rates in regard to COPD, use of medication, and smoking habits
No. of patients Expansion*
Unpaired t test Mann-Whitney test
Condition Yes No Yes No P value P value
COPD 14 96 2.7 2.7 .98 .70
b -Agonist treatment 13 97 3.6 2.6 .25 .17
Steroid treatment 12 98 3.8 2.6 .22 .06
Oral steroid treatment 8 106 4.7 2.6 .06 .00
b -Antagonist treatment 17 93 2.2 2.83 .57 .14
Smoking 41 69 3.2 1.9 .03 .03
*Mean annual expansion was calculated as follows: [(Current anteroposterior diameter – Initial anteroposterior diameter) ÷ Days of
observation] · 364.25 days.
Table V. Multiple regressions analysis: Mean annual expansion of small abdominal aortic aneurysm as
dependent variable
b Coefficient
Independent variable Mean value b Coefficient (95% CI) Partial F score
Initial size of AAA (mm) 34.7 0.22 0.15 to .28 38.63*
Serum elastin peptide (mg/L) 34.5 0.06 0.02 to .10 8.87*
FEV1 (L/s) 2.289 0.01 0.00 to .01 9.95*
b -Agonist treatment (yes = 1, no = 0) 0.09 1.58 0.13 to 3.02 4.57*
Steroid treatment (yes = 1, no = 0) 0.12 –0.53 –1.78 to .72 0.70
Smoking (yes = 1, no = 0) 0.57 0.11 –0.63 to .87 0.09
a 1-Antitrypsin (g/L) 1.42 0.34 –0.20 to .88 1.49
Diastolic blood pressure (mm Hg) 94.3 0.001 –0.02 to .03 0.12
Plasma elastase–a 1-antitrypsin complexes (mg/L) 70.2 0.02 –0.06 to .12 0.26
Mean annual expansion was calculated as follows: [(Current anteroposterior diameter – Initial anteroposterior diameter) ÷ Days of obser-
vation] · 364.25 days.
Predicted annual expansion (mm/y) = –8.81 + 0.22 (initial AAA size) + 0.06 (serum elastin peptides) + 0.01 (FEV1) + 1.58 (b -agonist)
– 0.53 (steroid use) + 0.11 (smoking) + 0.35 (a 1-antitrypsin) + 0.001 (diastolic blood pressure) + 0.02 (plasma elastase–a 1-antitrypsin
complexes).
*P < .05.
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smoking and use of various drugs. The level of
serum elastin peptides was significantly higher
among b -agonist users and steroid users, and smok-
ing increased mean concentrations of plasma and
serum elastase– a 1-antitrypsin complexes and a 1-
antitrypsin.
DISCUSSION
Methods. All persons in Denmark are regis-
tered at birth with a number used for registration of
address and hospital admissions. All inhabitants con-
sequently can be traced and their records used for
epidemiologic research, making selection bias
impossible. Only hospital diagnoses of AAA-associ-
ated diseases were used in this study. Consequently
some cases of AAA-associated disease must have
been unrecorded. On the other hand, valid diag-
noses rather than presumed diagnoses at the general
practitioner’s office must be expected.
Selection bias in blood sampling may have
occurred. However, measurement of elastase– a 1-
antitrypsin complexes requires a standardized
method.26 We could not assume that general techni-
cians would respect this method, so we performed
the measurements ourselves and could not incorpo-
rate them in the daily screening sessions. Therefore
we used 1 day a week blood sampling. However,
none of the tested nonserologic variables differed
between those having a blood sample taken and
those who did not have a sample taken.
Clinical observations. Earlier studies have
shown an increased prevalence of AAA among
patients with COPD.1,2 Our results confirmed this,
but when we controlled for coexisting AAA-associ-
ated diseases, the increased crude odds ratio of 2.05
was bisected to an adjusted odds ratio of 1.59. This
finding suggested that the reported increased preva-
lence may be partly explained by confounding from
coexisting AAA-associated diseases. This finding is
supported by the observation that the mean aortic
diameter of patients with and patients without AAA
and the mean annual expansion of small AAAs were
the same among patients without COPD and
patients with COPD suggesting COPD does not
increase aortic dilatation. Furthermore, FEV1 had a
surprising positive correlated with expansion of
AAA, that is increased expansion with increasing
FEV1.
Different elastolytic pathogenesis? The clini-
cal observations contrast to the observations of
increased serum elastin peptide concentration
among patients with COPD and a positive correla-
tion between serum elastin peptide concentration
and AAA expansion. However, this observation
would be explained if the elastin degradation caused
by elastase plays an important role in the pathogen-
esis of COPD but not in the pathogenesis of AAA.
The most important part of degradation of the aorta
might be caused by hypertension, the presence of
matrix metalloproteases, and the presence of non-
specific proteases that have been reported to be
abnormally elevated and activated in the presence of
AAA.42-46 This hypothesis is supported by the
observation of higher concentrations of plasma elas-
tase– a 1-antitrypsin complexes and serum a 1-anti-
trypsin among patients with COPD with no correla-
tion with expansion of AAA. This contrasts to
reports of a fourfold higher concentration in the
presence of ruptured AAA.21 However, inflamma-
tion causes increased secretion of elastase, and intra-
abdominal bleeding produces a marked inflammato-
ry response.26
Pharmacologic influence on elastolysis? Oral
therapy with steroids was associated with greater
expansion, and b -agonist treatment was an indepen-
dent, positively correlated predictor of expansion,
suggesting that medications used to manage COPD
may predispose patients to AAA. This suggestion is
amplified by the observation of increased levels of
serum elastin peptides among b -agonist users and
Table VI. Mean concentration of serum elastin peptide, plasma and serum elastase–a 1-antitrypsin com-
plexes, and a 1-antitrypsin in relation to smoking and use of various drugs
b -Agonist Steroid b -Blocker
treatment treatment treatment Smoking
Substance Yes No Yes No Yes No Yes No
Serum elastin peptide (mg/L) 39.7* 32.4 38.8* 32.2 32.6 33.2 34.7 31.5
Plasma elastase–a 1-antitrypsin (mg/L) 81.7 68.6 86.8* 68.1 79.1 68.5 76.0* 61.0
Serum elastase–a 1-antitrypsin (mg/L) 276.1 186.0 294.4 184.9 199.0 195.8 229.7* 145.3
a 1-Antitrypsin (g/L) 1.49 1.48 1.51 1.48 1.32 1.51 1.64* 1.25
*Mann Whitney test comparing levels of yes and no P < .05.
steroid users. Serum elastin peptides reflect the
degree of elastolysis and have been recommended
for monitoring elastolytic diseases such as emphyse-
ma13,14,47 and are reported to be an independent
predictor of the expansion of small AAAs.18
Steroid treatment has been suspected to influ-
ence the pathogenesis of AAA.48,49 Use of b -ago-
nists and b -blockers was analyzed because of earlier
reports of lower expansion among users of b -block-
ers.50-52 The possible effect of use of b -blockers is
hypothesized to be increased cross linkage of colla-
gen and elastin.53 We noticed an insignificant trend,
but our data suggested a reverse reaction with the
use of b -agonists. 
If management of COPD damages the elastic tis-
sue of the aorta, one may fear the consequences to pul-
monary elastic tissue with permanent inhalation treat-
ment, especially because a gradual increase in mortali-
ty rates for asthma was seen worldwide during the last
decade.54 Results of pharmacoepidemiologic studies
indicate a strong association between increased b -ago-
nist treatment and asthma deaths.55 The predominant
causes of death are status asthmaticus and chronic
asthma correlated with increased reversibility of FEV1,
that is, a chief motivation for b -agonist treatment.56
However, a larger study must be conducted for clarifi-
cation of this suspicion, considering the consequences
of a conclusion of elastolytic damage by antiasthma
drugs and the limited numbers of patients involved in
this study.
Concentration of serum elastin peptide as a
predictor of expansion of abdominal aortic
aneurysm. Indications for operation are determined
by the size of the AAA. However, small AAAs do
occasionally rupture, and some surgically managed
AAAs never would have ruptured.57-63 Furthermore,
a number of these small, conservatively treated AAAs
expand to operation-necessitating size, but the
patients are older and at increased risk during an
operation or eventually an operation is contraindicat-
ed. Therefore a more nuanced indication for opera-
tion would be desirable, but valid predictors are miss-
ing. In a 1-year follow-up study,18 we found serum
elastin peptides to be a relatively strong predictor of
expansion of AAA. However, optimizing the indica-
tion for operation demands valid long-term predic-
tions. Our results show that this quality is still present
after 2 years of follow-up study (Table V). 
Conclusion. The observations seems to suggest
that the increased prevalence of AAA among persons
with COPD is more likely to be caused by medica-
tion use and associated cardiovascular diseases than
by the proteolytic part of the pathogenesis of the pul-
monary disease. If b -agonist treatment destroys the
elastic tissue of the aorta, one may fear the conse-
quences to the pulmonary elastic tissue with perma-
nent inhalation treatment, which often is started in
childhood. A larger study is required for clarification.
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